36386-71-7

Upstream product

• 40396-67-6 2-[4-(1,1,2,2-Tetrafluoro-2-phenyl-ethyl)-phenyl]-propan-2-ol 
• 100-44-7 benzyl chloride 
• 2001-29-8 1-(4-bromophenyl)-2-phenyl-ethan-1-one 
• 623-00-7 4-bromobenzenecarbonitrile 
• 39229-12-4 4-bromobenzil 
• 40396-59-6 1-phenyl-2-p-bromophenyltetrafluoroethane 
• 40417-83-2 N-{1-Methyl-1-[4-(1,1,2,2-tetrafluoro-2-phenyl-ethyl)-phenyl]-ethyl}-formamide 

Downstream Products

• 41485-24-9 1-(1-Methyl-1-nitro-ethyl)-4-(1,1,2,2-tetrafluoro-2-phenyl-ethyl)-benzene 
• 38375-71-2 4-(α,α,β,β-Tetrafluorophenethyl)-α,α,N,N-tetramethylbenzylamine 

Relevant academic research and scientific papers

2, 3, and 4 (α,α,β,β Tetrafluorophenethyl)benzylamines. A new class of antiarrhythmic agents

Upon finding 2-(α,α,β,β-tetrafluorophenethyl)benzylamine (4) to be a potent and novel type of antiarrhythmic agent, 2-, 3-, and 4-(α,α,β,β-Tetrafluorophenethyl) benzylamines were synthesized. Structure-activity relationships in this series are described.

Mass spectral identification of the metabolites of alpha,alpha-dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl)-benzylamine (MK-251), a novel antiarrhythmic agent, in various species.

The identification of a number of metabolites of the novel antiarrhythmic agent, alpha,alpha-dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl)benzylamine (MK-251), is presented. The compound is extensively metabolized by dog, monkey, baboon and man.

Tetrafluorophenethylaralkylamine compounds

New fluoro derivatives of aralkylamine compounds, particularly 2-(2-phenyl-1,1,2,2-tetrafluoroethyl)benzylamine, as well as the N-alkyl and the N,N-dialkyl derivatives thereof are prepared by reaction of 2-bromobenzonitrile with benzylmagnesium chloride to produce 2'-bromo-2-phenylacetophenone; oxidation of said acetophenone with selenous acid to produce 2-bromobenzil; conversion of the benzil compound by treatment with sulfur tetrafluoride to the corresponding 2-bromo-α ,α-α',α'-tetrafluorobibenzyl; followed by reaction of the 2-bromobibenzyl compound with a metal cyanide to produce the corresponding 2-(2-phenyl-1,1,2,2-tetrafluoroethyl)benzonitrile. This nitrile compound is then reduced with lithium aluminum hydride to produce the corresponding benzylamine, which is then converted, if desired, to the N-alkyl and/or N,N-dialkyl 2-(2-phenyl-1,1,2,2-tetrafluoroethyl)benzylamine. Alternatively, the nitrile or the precursor bromobibenzyl can be converted by Grignard reactions to the corresponding α-alkyl or α,α-dialkylbenzylamine which can then be converted if desired to the corresponding N-alkyl and/or N,N-dialkyl substituted benzylamine compound. The phenyltetrafluoroethylbenzylamine as well as its N-alkyl and N,N-dialkyl derivatives are active as antiarrhythmic agents.